Pott截瘫患者血清中神经丝轻链蛋白的表达水平及与神经症状的相关研究进展

ISSN:2705-098X(P)

EISSN:2705-0505(O)

语言:中文

作者
胡锦成,鲍剑峰
文章摘要
Pott截瘫是脊柱结核的严重并发症之一,其特征为下肢运动和感觉功能障碍。近年来,一些研究开始关注Pott截瘫患者血清中神经丝轻链蛋白(NFL)的表达水平及其与神经症状的关联性。本综述旨在总结和分析已发表的相关研究,以增进对NFL在Pott截瘫中的潜在作用的理解。通过文献检索,我们找到了多篇研究报告,其中对Pott截瘫患者血清中NFL表达水平进行了评估,并与神经症状进行了相关性分析。结果显示,Pott截瘫患者血清中NFL表达水平明显升高。这一升高可能与脊柱结核骨质破坏造成的神经损伤有关。此外,高NFL水平与疾病的严重程度和脊柱畸形的发展有关。与神经症状的相关性研究表明,高NFL水平与下肢运动和感觉障碍的存在呈正相关。这提示NFL可能作为一个潜在的生物标记物,用于评估Pott截瘫的严重程度和预测病情的进展。另外,一些研究还发现NFL与膀胱和直肠功能障碍之间存在相关性,进一步支持了NFL在Pott截瘫中的潜在作用。尽管这些研究结果表明血清中NFL可能在Pott截瘫的评估和监测中具有潜在的临床应用价值,但还需要更多的研究来验证这些发现,并进一步探索NFL在Pott截瘫患者中的具体作用机制。
文章关键词
神经丝轻链蛋白;脊柱结核;Pott截瘫;神经症状;生物标志物
参考文献
[1] GAETANI L,BLENNOW K,CALABRESI P,et al.Neurofilament light chain as a biomarker in neurological disorders[J].Journal of Neurology,Neurosurgery&Psychiatry,2019,90(8):870-81. [2] THEBAULT S,BOOTH R A,FREEDMAN M S.Blood neurofilament light chain:the neurologist’stroponin?[J].Biomedicines,2020,8(11):523. [3] LADANG A,KOVACS S,LENGELéL,et al.Neurofilament light chain concentration in an aging population[J].Aging Clinical and Experimental Research,2022,34(2):331-9. [4] KHALIL M,TEUNISSEN C E,OTTO M,et al.Neurofilaments as biomarkers in neurological disorders[J].Nature Reviews Neurology, 2018,14(10):577-89. [5] KöLLIKER FRERS R A,OTERO-LOSADA M,KOBIEC T,et al.Multidimensional overview of neurofilament light chain contribution to comprehensively understanding multiple sclerosis[J].Frontiers in Immunology,2022,13:912005. [6] BALASTIK M,FERRAGUTI F,PIRES-DA SILVA A,et al.Deficiency in ubiquitin ligase TRIM2 causes accumulation of neurofilament light chain and neurodegeneration[J].Proceedings of the National Academy of Sciences,2008,105(33):12016-21. [7] NOVAKOVA L,ZETTERBERG H,SUNDSTRöM P,et al.Monitoring disease activity in multiple sclerosis using serum neurofilament light protein[J].Neurology,2017,89(22):2230-7. [8] KUHLE J,BARRO C,ANDREASSON U,et al.Comparison of three analytical platforms for quantification of the neurofilament light chain in blood samples:ELISA,electrochemiluminescence immunoassay and Simoa[J].Clinical Chemistry and Laboratory Medicine (CCLM),2016,54(10):1655-61. [9] CLAIRE A L,JOHN C,NICOLAS R B,et al.Development of a targeted proteomic assay for the quantitation of neurofilament light in cerebrospinal fluid:Correlation with Simoa‐based quantitation across neurodegenerative diseases and centres[J].2023,19. [10] ARSLAN B,ZETTERBERG H.Neurofilament light chain as neuronal injury marker–what is needed to facilitate implementation in clinical laboratory practice?[J].Clinical Chemistry and Laboratory Medicine(CCLM),2023,61(7):1140-9. [11] ALIREZAEI Z,POURHANIFEH M H,BORRAN S,et al.Neurofilament light chain as a biomarker,and correlation with magnetic resonance imaging in diagnosis of CNS-related disorders[J].Molecular neurobiology,2020,57:469-91. [12] CLAIRE A L,JOHN B C,TATIANA A G,et al.Cerebrospinal fluid neurofilament light chain profiling and quantitation in neurological diseases[J].Brain communications,2024. [13] TAKUMI N,TAKESHI K,YOSHIO I,et al.High levels of plasma neurofilament light chain correlated with brainstem and peripheral nerve damage[J].Journal of the Neurological Sciences,2024,463:123137-. [14] AHMED N,SHAHIDUL ISLAM KHAN M,KAMRUL AHSAN M.Pott’s Paraplegia[M].Paraplegia-New Insights.IntechOpen.2023. [15] RIDHAM R D,JASSAL Y D,SATODIYA M D.Pott's Spine manifesting as paraplegia in pregnancy and its management:A case report[J].INDIAN JOURNAL OF APPLIED RESEARCH,2024:40-1. [16] SARKAR R,SARKAR S,PRAMANIK A,et al.Pott’s paraplegia-satisfactory outcome in spite of poor prognostic factors,treated by a novel surgical technique of posterior spinal stabilization and anterolateral decompression with bone graft fusion:a case report[J].Int J Res Med Sci,2024,12(6):2137-42.
Full Text:
DOI